Skip to content

Asarina Pharma: New cross-border Board reflects global potential of therapy

Stockholm – May 31, 2018. Asarina Pharma’s new Board reflects the global potential of its first-in-class therapy for PMDD. New members include senior pharma, science and research professionals from a range of countries contributing a powerful mix of skills.

In spring Asarina Pharma launched the Phase IIB trials of Sepranolone, its first-in-class therapy for PMDD, the highly debilitating severest form of PMS. Set to involve 250 patients in four different countries, the new trials reflect Sepranolone’s international potential. As does Asarina Pharma’s new Board of Directors.

With senior pharma, science, finance and business professionals from Sweden, Denmark, France, Poland and the UK, the Board represents many decades of scientific and business expertise. Current member Ola Fink will stay on the Board, but step down as Chairman.

New Chairman Paul de Potocki, current CBO of RSPR Pharma, will be one of three new faces. Paul has extensive experience in international leadership, commercial operations and business & corporate development and financial management in both public and PE/VC-owned companies.

New member André Ulmann, currently CEO at CEMAG Consulting in Paris, was the Founder of HRA Pharma, a company he led from 1996 to 2009 as CEO, then chaired until 2016. Dr. Ulmann served as Medical Director and Head of Clinical Research for Roussel-Uclaf and Hoechst-Marion-Roussel before founding HRA Pharma, and began his career at the Necker Hospital, Paris.

New member Marianne Kock is currently SVP at Ferring Pharmaceuticals in Copenhagen. With decades of experience in R&D, clinical development, regulatory affairs and pharma development. Marianne is a Graduate of Danmarks Farmaceutiske Universitet and before joining Ferring in 2002 was Vice President of Novo Nordisk.

Current Board member Peter Nordkild (now CEO) will resign. Current members Thierry Laugel, Graham Flagg, Otto Skolling and Miroslav Reljanovic remain.